# PHARMACOLOGICAL TARGETING OF GALPHA SUBUNITS IN DISEASE

> **NIH NIH R01** · WASHINGTON UNIVERSITY · 2024 · $460,566

## Abstract

Project Summary/Abstract
 This multi-PI basic science project aims to transform understanding of G-protein function in physiology
and disease, and provide broadly applicable routes for developing therapeutics to treat currently untreatable
diseases caused by mutant constitutively active G protein α-subunits. It does so by developing knowledge
required to design and synthesize, at scales required for preclinical and eventual clinical studies, a family of
bioavailable inhibitors, each of which selectively targets closely related groups of heterotrimeric G proteins.
The translational/clinical potential of this approach is based on recent studies indicating that a bioavailable
inhibitor that targets G protein α-subunits of the Gq/11 class is therapeutically effective in mouse models of
uveal melanoma, an untreatable disease that is driven by mutant constitutively active Gq/11. Similar
approaches could have broad impact, because many other untreatable diseases are driven by various types of
mutant constitutively active G protein α-subunits, including hormone-secreting pituitary tumors, mucosal
melanoma, choroidal hemangiomas, hepatic small-vessel neoplasms, ~10-15% of all cancers, Sturge-Weber
syndrome, autosomal dominant hypoparathyroidism, and certain forms of hyper- and hypocalcemia. Moreover,
this approach could be used to modulate G-protein activity in diseases where GPCR-targeted drugs are
ineffective due to receptor redundancy or to G proteins that cause dose-limiting side effects such as
respiratory suppression or drug tolerance.
 Bioavailable inhibitors that directly target specific subclasses of G proteins would be extremely valuable
for basic science. They would provide simple, fast, cheap and reliable chemical probes with which to identify
novel functions of G proteins in normal physiology and in animal models of disease, in contrast to conventional
knockout or knockdown strategies, which are slow and expensive, and can suffer from compensatory or off-
target effects.
 The foundation of this project is a pair of nearly identical, bioavailable, cyclic depsipeptide natural
products that potently and selectively inhibit the Gq/11 subfamily of G protein α-subunits. The Specific Aims of
this project will address four crucial challenges: 1) limited availability of these inhibitors; 2) lack of inhibitor
derivatives that could be targeted to disease tissues for chronic therapy; 3) limited understanding of the
inhibitory mechanism, which has precluded design of inhibitors that target other subtypes of G proteins; and 4)
absence of inhibitors that selectively target G protein subtypes other than Gq/11. These Aims will be pursued
by using innovative synthetic organic chemistry, computational-based docking and inhibitor design, single-
molecule FRET, NMR, and biochemical and cell-based assays of G protein function.

## Key facts

- **NIH application ID:** 10886688
- **Project number:** 5R01GM124093-08
- **Recipient organization:** WASHINGTON UNIVERSITY
- **Principal Investigator:** Kendall J Blumer
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $460,566
- **Award type:** 5
- **Project period:** 2017-08-01 → 2026-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10886688

## Citation

> US National Institutes of Health, RePORTER application 10886688, PHARMACOLOGICAL TARGETING OF GALPHA SUBUNITS IN DISEASE (5R01GM124093-08). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10886688. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*